Herpesvirus 4, Human

• 

  Subject Areas on Research

  • A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo. 
  • A human anti-HIV autoantibody enhances EBV transformation and HIV infection. 
  • A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly. 
  • A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. 
  • Absence of human herpes virus 8 DNA sequences in large granular lymphocyte (LGL) leukemia. 
  • Acute leukemia in Burkitt lymphoma. 
  • Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children. 
  • Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. 
  • Adoptively transferred immunity persists in human marrow graft recipients. 
  • An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. 
  • An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. 
  • An Epstein-Barr virus-positive classical Hodgkin lymphoma with exclusive sinusoidal growth pattern: An unusual morphologic variant. 
  • An uncommon presentation of non-Hodgkin's lymphoma in a renal transplant recipient. 
  • Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. 
  • Anti-EBV serologic tests for nasopharyngeal carcinoma. 
  • Antibody-dependent cellular cytotoxicity and disease course in North American patients with nasopharyngeal carcinoma: a prospective study. 
  • Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. 
  • Application of Epstein-Barr virus serology to the diagnosis and staging of North American patients with nasopharyngeal carcinoma. 
  • Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. 
  • Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. 
  • Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. 
  • CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. 
  • Characterization of an Epstein-Barr virus receptor on human epithelial cells. 
  • Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. 
  • Characterization of the EBV-Induced Persistent DNA Damage Response. 
  • Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced infectious mononucleosis. 
  • Complement receptor expression by neoplastic and normal human cells. 
  • Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. 
  • Comprehensive molecular characterization of gastric adenocarcinoma. 
  • Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus. 
  • Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. 
  • Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. 
  • Delayed onset of infectious mononucleosis associated with acquired agammaglobulinemia and red cell aplasia. 
  • Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. 
  • Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. 
  • Development of suppressor T lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: assessment by two quantitative systems. 
  • Dissociation of opsonized particle phagocytosis and respiratory burst activity in an Epstein-Barr virus-infected myeloid cell line. 
  • Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 
  • Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation. 
  • EBV BART MicroRNAs Target Multiple Pro-apoptotic Cellular Genes to Promote Epithelial Cell Survival. 
  • EBV Noncoding RNAs. 
  • EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? 
  • Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. 
  • Effects of cyclosporine on human B-cell lymphoma development in vivo. 
  • Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. 
  • Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. 
  • Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. 
  • Epstein-Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia. 
  • Epstein-Barr Viruses (EBVs) Deficient in EBV-Encoded RNAs Have Higher Levels of Latent Membrane Protein 2 RNA Expression in Lymphoblastoid Cell Lines and Efficiently Establish Persistent Infections in Humanized Mice. 
  • Epstein-Barr in acute nontraumatic mononeuropathies. 
  • Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. 
  • Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. 
  • Epstein-Barr virus and Guillain-Barrè syndrome. 
  • Epstein-Barr virus and chronic lymphadenomegaly in male homosexuals with acquired immunodeficiency syndrome (AIDS). 
  • Epstein-Barr virus and the elderly host. 
  • Epstein-Barr virus antibodies in whole blood spots: a minimally invasive method for assessing an aspect of cell-mediated immunity. 
  • Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. 
  • Epstein-Barr virus ensures B cell survival by uniquely modulating apoptosis at early and late times after infection. 
  • Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. 
  • Epstein-Barr virus in synergy with tumor-promoter-induced malignant transformation of immortalized human epithelial cells. 
  • Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency. 
  • Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. 
  • Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. 
  • Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. 
  • Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. 
  • Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. 
  • Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. 
  • Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. 
  • Epstein-Barr virus-associated smooth muscle tumor involving the spine of an HIV-infected patient: Case report and review of the literature. 
  • Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. 
  • Epstein-Barr virus-negative diffuse large B cell lymphoma with aberrant expression of CD3 and other T cell-associated antigens: report of three cases with a review of the literature. 
  • Epstein-Barr virus-related posttransplantation lymphoproliferative disorder involving pancreas allografts: histological differential diagnosis from acute allograft rejection. 
  • Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. 
  • Evolutionary conservation of primate lymphocryptovirus microRNA targets. 
  • Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. 
  • Factors associated with recurrent cytomegalovirus disease after small bowel transplantation. 
  • Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma. 
  • Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. 
  • Generation of tumor-specific T lymphocytes for the treatment of posttransplant lymphoma. 
  • High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. 
  • Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus. 
  • Human epithelial cell expression of an Epstein-Barr virus receptor. 
  • Improved EBV shuttle vectors. 
  • In situ detection of Epstein-Barr virus in non-small cell lung carcinomas. 
  • Induction of complement receptor expression in cell lines derived from human undifferentiated lymphomas. II. Characterization of the induced complement receptors and demonstration of the simultaneous induction of EBV receptor. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Infection of normal human thymic epithelial cells by Epstein-Barr virus (EBV) following implantation of EBV receptors. 
  • Isolation of human sequences that replicate autonomously in human cells. 
  • Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. 
  • Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. 
  • Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. 
  • Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. 
  • Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. 
  • Lymphoproliferative disorders: CT findings in immunocompromised children. 
  • MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. 
  • Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation. 
  • Meralgia paraesthetica and Epstein-Barr virus. 
  • Metabolic stress is a barrier to Epstein-Barr virus-mediated B-cell immortalization. 
  • Molecular analysis of thymopentin binding to HLA-DR molecules. 
  • Molecular basis of latency in pathogenic human viruses. 
  • Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. 
  • Multilocular thymic cysts in children with human immunodeficiency virus infection: clinical and pathologic aspects. 
  • Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. 
  • Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. 
  • Necrotizing lymphoid vasculitis in X-linked lymphoproliferative syndrome. 
  • Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. 
  • Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). 
  • Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. 
  • Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals. 
  • Production of a human monoclonal antibody to HLA by human-human hybridoma technology. A preliminary report. 
  • Proteins of purified Epstein-Barr virus. 
  • RNA: jack of all trades and master of all. 
  • Rasmussen's syndrome: a study of potential viral etiology. 
  • Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation. 
  • Replication control of autonomously replicating human sequences. 
  • Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. 
  • Role of Epstein-Barr virus in the etiology of Burkitt's lymphoma. 
  • SplicerEX: a tool for the automated detection and classification of mRNA changes from conventional and splice-sensitive microarray expression data. 
  • Squamous-cell carcinoma, Kaposi's sarcoma and Burkitt's lymphoma are consequences of impaired immune surveillance of ubiquitous viruses in acquired immune deficiency syndrome, allograft recipients and tropical African patients. 
  • Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. 
  • Successful immune reconstitution in severe combined immunodeficiency despite Epstein-Barr virus and cytomegalovirus infections. 
  • T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. 
  • The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. 
  • The Epstein-Barr virus miR-BHRF1 microRNAs regulate viral gene expression in cis. 
  • The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma. 
  • The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. 
  • The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. 
  • The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes. 
  • The role of Epstein-Barr virus in systemic lupus erythematosus. 
  • The role of microRNAs in Epstein-Barr virus latency and lytic reactivation. 
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. 
  • The viral and cellular microRNA targetome in lymphoblastoid cell lines. 
  • To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis. 
  • Transformation of hairy cell leukemia to EBV genome-containing aggressive B cell lymphoma. 
  • Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. 
  • Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. 
  • [Studies on human porin. V. The expression of "porin31HL" in the plasmalemma is not by cell transformation] 
  • c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Professor of Pediatrics, in the School of Medicine, Immunology
  • Luftig, Micah Alan, Associate Professor of Molecular Genetics and Microbiology, Immunology